The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
1d
GlobalData on MSNPfizer sets sights on Summit’s bispecific in combo with its ADCsPfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Parents of a girl from Cleveland say a recent Super Bowl ad from Pfizer gives the wrong idea about childhood cancer treatment.We've told you about Olivia Weathe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results